Patents by Inventor Patrick McKee
Patrick McKee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10654761Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.Type: GrantFiled: August 31, 2018Date of Patent: May 19, 2020Assignee: Safariland, LLCInventors: John Hultman, Patrick McKee
-
Publication number: 20190071373Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.Type: ApplicationFiled: August 31, 2018Publication date: March 7, 2019Inventors: John Hultman, Patrick McKee
-
Patent number: 10174077Abstract: The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed inventive concept(s) also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed inventive concept(s) further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: GrantFiled: November 21, 2016Date of Patent: January 8, 2019Assignee: The Board of Regents of the University of OklahomaInventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Patent number: 10155789Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.Type: GrantFiled: May 23, 2017Date of Patent: December 18, 2018Assignee: The Board of Regents of the University of OklahomaInventors: Patrick A. McKee, Kenneth W. Jackson, Victoria J. Christiansen
-
Patent number: 10065897Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.Type: GrantFiled: May 14, 2015Date of Patent: September 4, 2018Assignee: Safariland, LLCInventors: John Hultman, Patrick McKee
-
Publication number: 20180154223Abstract: A customizable lacrosse head and a method of customizing a lacrosse head are provided. The head includes a head frame having opposed sidewalls extending between a throat and a scoop, each sidewall being capable of customization through machining, cutting, dying, or the like. In some embodiments, the sidewalls include one or more curved and/or angled portion, at least part of such portion being customizable. In some embodiments, the method of customizing the head includes deforming the head frame around a machining block prior to cutting and/or machining the deformed head frame. In some embodiments, the method of customizing the head includes using a press to dye one or more portion of the head frame.Type: ApplicationFiled: December 4, 2017Publication date: June 7, 2018Inventor: Thomas Patrick McKee
-
Publication number: 20170260231Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.Type: ApplicationFiled: May 23, 2017Publication date: September 14, 2017Inventors: Patrick A. McKee, Kenneth W. Jackson, Victoria J. Christiansen
-
Patent number: 9688722Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.Type: GrantFiled: May 3, 2013Date of Patent: June 27, 2017Assignee: The Board of Regents of the University of OklahomaInventors: Patrick A. McKee, Kenneth W. Jackson, Victoria J. Christiansen
-
Publication number: 20170066800Abstract: The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed inventive concept(s) also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed inventive concept(s) further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Inventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Patent number: 9527884Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: GrantFiled: January 8, 2015Date of Patent: December 27, 2016Assignee: The Board of Regents of the University of OklahomaInventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Publication number: 20150329437Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.Type: ApplicationFiled: May 14, 2015Publication date: November 19, 2015Inventors: John Hultman, Patrick McKee
-
Publication number: 20150141660Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: ApplicationFiled: January 8, 2015Publication date: May 21, 2015Inventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Patent number: 8933201Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: GrantFiled: December 15, 2010Date of Patent: January 13, 2015Assignee: The Board of Regents of the University of OklahomaInventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Publication number: 20140260830Abstract: A seal-break pliers used to separate components in food processing, chemical, or pharmaceutical manufacturing or processing system. The seal-break pliers including a first section and a second section. Each section includes a handle, a head section, and a transition section disposed and angularly orientated between the handle and the head section. A fastener pivotally couples the first section to the second section such that displacing the first and second handles toward each other results in a relative movement of the head sections toward each other. Each head portion includes a guide projection, a flange notch adjacent to the guide projection, and a wedge projection adjacent to the flange notch. The flange notch is configured to receive a portion of the flange of a component. The wedge projection may include a pointed edge proximate the flange notch and an inclined surface extending away from the pointed edge.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: SRM, LLC dba Holloway AmericaInventors: Charles Patrick McKee, David E. Simpson
-
Publication number: 20110144037Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: ApplicationFiled: December 15, 2010Publication date: June 16, 2011Inventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Patent number: 7552517Abstract: An apparatus and method are provided for clamping a belt with a quick clamping action. The apparatus and method employ an impact force applied to a clamping device that causes a clamping portion of the clamping device to be driven into clamping engagement with the belt received in a housing for the clamping device. In one form, the clamping device has a clamp actuator that includes an impact receiving end preferably disposed outside the housing and a clamp member in the housing that is driven into clamping engagement with the belt by the actuator. The preferred belt clamp has the actuator and clamp member configured so that during belt pulling operations, the clamp also self-locks onto the belt to increase the clamping force applied thereto. In another aspect, the housing preferably has wall portions of varying thickness to provide increased strength where needed while keeping the weight thereof to a minimum.Type: GrantFiled: October 16, 2006Date of Patent: June 30, 2009Assignee: Flexible Steel Lacing CompanyInventor: James Patrick McKee
-
Publication number: 20080314051Abstract: An apparatus and method for cryogenic processing comprising a chamber having a specially optimized configuration and geometry and having internal insert array of pathways and supporting elements to facilitate advanced materials processing. The pathways and supporting components can be configured by bending and positioning in different planes with bending the pathways with optimal radii and in different planes. The pathways bending radii can be within an optimal range for the size of the chamber and the angles between the pathway bending planes can be within an optimal range. The angles between the supporting components positioning planes and the pathway bending planes can be in an optimal range. The invention can also include structural supporting components that are attached at the pathway small movement points and the length of attachment can vary from about approximately zero to the full length of the supporting component.Type: ApplicationFiled: February 14, 2008Publication date: December 25, 2008Inventor: Charles Patrick McKee
-
Publication number: 20080118933Abstract: Human ?2-antiplasmin (?2AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of ?2AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or ?2APpro and an N-terminally-shortened 452-residue “activated”-form, or ?2APact. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than ?2APpro and makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of ?2APpro to yield ?2APact. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE). Novel inhibitors of circulating APCE can diminish ?2AP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin.Type: ApplicationFiled: November 20, 2007Publication date: May 22, 2008Inventors: Patrick McKee, Kyung Lee, Kenneth Jackson, Victoria Christiansen
-
Publication number: 20080086849Abstract: An apparatus and method are provided for clamping a belt with a quick clamping action. The apparatus and method employ an impact force applied to a clamping device that causes a clamping portion of the clamping device to be driven into clamping engagement with the belt received in a housing for the clamping device. In one form, the clamping device has a clamp actuator that includes an impact receiving end preferably disposed outside the housing and a clamp member in the housing that is driven into clamping engagement with the belt by the actuator. The preferred belt clamp has the actuator and clamp member configured so that during belt pulling operations, the clamp also self-locks onto the belt to increase the clamping force applied thereto. In another aspect, the housing preferably has wall portions of varying thickness to provide increased strength where needed while keeping the weight thereof to a minimum.Type: ApplicationFiled: October 16, 2006Publication date: April 17, 2008Inventor: James Patrick McKee
-
Publication number: 20080057491Abstract: The present invention is directed toward inhibitors of antiplasmin cleaving enzyme for use in various therapies related to fibrin and ?2-antiplasmin, and to substrates of APCE, which may be used, for example, in screening methods for identifying such inhibitors. The present invention is further directed to methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the rations of types of plasma ?2-antiplasmin.Type: ApplicationFiled: June 6, 2007Publication date: March 6, 2008Inventors: Patrick McKee, Kyung Lee, Kenneth Jackson, Victoria Christiansen